Can Self-Compassion training boost mental health in transgender youth?
NCT ID NCT06409975
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether an 8-week virtual mindful self-compassion program is practical and well-received by transgender and nonbinary young adults. Participants attend weekly 2.5-hour online classes plus a 4-hour retreat, practice daily exercises, and complete surveys over several months. The goal is to see if this approach is feasible and acceptable, not yet to measure its effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Mindful Self-Compassion (MSC) program
- What this could lead to
- If successful, this could provide a tailored mental health support option for transgender and nonbinary young adults, potentially improving emotional well-being.
- What could go wrong
- This is a small, early feasibility study with no control group, so results may not prove effectiveness. The program requires a significant time commitment, which may limit participation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 29 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * transgender, nonbinary, genderqueer (or another non-cisgender identity) * have reliable access to a smart phone or computer/tablet and the Internet and is reasonably able to make the time commitment required of the program (self-report) * speak and understand English Exclusion Criteria: * has had formal mindfulness training (i.e. mindfulness-based stress reduction course) or engages in regular mindfulness practice (15 minutes more than twice a week for the last six months or more) * Score 15 or higher on the patient health questionnaire-8 (PHQ-8) * Score 2 or higher on the Columbia Suicide Severity Rating Scale * Experienced an acute physical health crisis (e.g., chemotherapy, recovery from severe injury) (Germer \& Neff, 2019, p. 80) in the past year * Head trauma, seizure, or loss of consciousness in the past 6 months * Reports a history of trauma AND Scores 14 or higher on Post-Traumatic Checklist, 6-item Civilian version * Reports a diagnosis of a personality disorder * Reports a diagnosis of schizophrenia or a history of psychosis * Reports acute panic attack in the past month and history of acute panic attacks with concern/worry about having another one in the future OR Reports severe social anxiety which would make attending class too difficult * Reports an acute episode of psychosis or suicide attempt in the past 12 months * Has engaged in non-suicidal self-injury in the past 6 months * Currently prescribed antipsychotic medications, benzodiazepine (equivalent to 30mg diazepam/day) or opioids (\>40mg morphine equivalent/day) * Prescribed any other psychiatric medication, including medication for opioid use disorder, whose dose has been changed in the past 8 weeks or is anticipated to change in the next 2 months. * Currently engage in harmful drinking (5 or more drinks on one occasion (Flentje et al., 2020) more than once in the past 2 weeks; OR have any concerns about the expectation to not be using substances during group sessions * has undergone detoxification from alcohol or other drugs and has been in sustained remission (with or without medication) for less than 1 year * Has been hospitalized overnight for mental health related reasons in the past year (any diagnoses except bipolar disorder) OR have a diagnosis of bipolar disorder and have had an episode of mania or have been hospitalized in the past 2 years * Reports any other acute physical or mental illness symptoms that may make group participation difficult
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
N/A-- All study activities being conducted virtually
RECRUITINGProvidence, Rhode Island, 02903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?